Gallagher, Emily J.
Fei, Kezhen
Feldman, Sheldon M.
Port, Elisa
Friedman, Neil B.
Boolbol, Susan K.
Killelea, Brigid
Pilewskie, Melissa
Choi, Lydia
King, Tari
Nayak, Anupma
Franco, Rebeca
Cruz, Daliz
Antoniou, Irini M.
LeRoith, Derek
Bickell, Nina A.
Funding for this research was provided by:
National Cancer Institute (R01CA171558, R01CA128799, K08CA190770)
Article History
Received: 27 January 2020
Accepted: 17 April 2020
First Online: 12 May 2020
Ethics approval and consent to participate
: Institutional Review Board approval was obtained at all participating sites, and patients consented to participate. All data were collected in adherence with the IRB protocols.
: All patients consented to participate in this study.
: SMF, NBF, SKB, LC, KF, AN, TK, RF, IMA, and DC report no potential conflicts of interest. EJG: advisory board for Novartis; DLR: advisory board for AstraZeneca and Mankind and consultant for Janssen; EP: stock ownership in Remedy Pharmaceuticals, Angiocrine, Viewpoint, TMRW; BK: advisory board for and honoraria from Genentech; NAB: research funding from Pfizer.